Risk-adapted use of intravesical chemotherapy.
作者信息
Lerner Seth P, Au Jessie L-S
机构信息
Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA.
出版信息
BJU Int. 2008 Nov;102(9 Pt B):1247-53. doi: 10.1111/j.1464-410X.2008.07967.x.
Abstract
摘要
相似文献
1
Risk-adapted use of intravesical chemotherapy.膀胱内化疗的风险适应性应用。
BJU Int. 2008 Nov;102(9 Pt B):1247-53. doi: 10.1111/j.1464-410X.2008.07967.x.
2
Intravesical chemotherapy.膀胱内化疗
Prog Clin Biol Res. 1984;162B:125-50.
3
Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation.膀胱内化疗与卡介苗免疫疗法对浅表性膀胱移行细胞癌复发的影响：荟萃分析再评估
Am J Clin Oncol. 2003 Aug;26(4):402-7. doi: 10.1097/01.COC.0000026911.98171.C6.
4
Risk-adapted use of intravesical immunotherapy.膀胱内免疫疗法的风险适应性使用。
BJU Int. 2008 Nov;102(9 Pt B):1254-64. doi: 10.1111/j.1464-410X.2008.07968.x.
5
Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.关于以下内容的编辑评论：与短期膀胱内化疗及卡介苗（BCG）短期治疗相比，长期膀胱内辅助化疗可进一步降低非肌层浸润性膀胱癌患者的复发率。
Eur Urol. 2007 Oct;52(4):1129-30. doi: 10.1016/j.eururo.2007.02.064.
6
Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.与短期膀胱内化疗以及非肌层浸润性膀胱癌患者的短期卡介苗（BCG）治疗相比，长期膀胱内辅助化疗可进一步降低复发率。
Eur Urol. 2007 Oct;52(4):1123-29. doi: 10.1016/j.eururo.2007.02.063. Epub 2007 Mar 12.
7
Point. Routine use of postoperative intravesical chemotherapy after TURBT-should it be done?
Urology. 2010 Oct;76(4):794-6. doi: 10.1016/j.urology.2010.04.069.
8
BCG versus cytotoxic chemotherapy in the treatment of superficial bladder tumors.卡介苗与细胞毒性化疗治疗浅表性膀胱肿瘤的对比
Prog Clin Biol Res. 1992;378:55-7.
9
10
[Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents].[浅表性膀胱肿瘤的术后及辅助膀胱内治疗。临床实践与应用治疗药物]
Aktuelle Urol. 2009 Sep;40(5):307-9. doi: 10.1055/s-0029-1224551. Epub 2009 Jul 27.
引用本文的文献
1
Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts.静脉注射小干扰RNA沉默生存素可增强丝裂霉素C在人膀胱RT4异种移植瘤中的活性。
J Urol. 2015 Jul;194(1):230-7. doi: 10.1016/j.juro.2015.02.036. Epub 2015 Feb 11.
2
Recent advances in the diagnosis and treatment of bladder cancer.膀胱癌的诊断与治疗新进展。
BMC Med. 2013 Jan 17;11:13. doi: 10.1186/1741-7015-11-13.
Zotero 插件